Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Bevacizumab + IFN probably leads to higher serious adverse events (Grade 3 or 4) compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.31 [1.2, 1.42]
2 studies · 1356 participants
Moderate

Pazopanib vs placebo (targeted agent versus placebo)

Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)

Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 2 [1.4, 2.85]
1 study · 435 participants
High